KMT2A and leukemia: By inhibiting the menin–KMT2A interaction, menin inhibitors reduce the chromatin binding and oncogenic effects of NPM1c, leading to decreased transcription of leukemia-promoting genes, ultimately promoting differentiation and reducing leukemic cell proliferation [20,21].